Glioblastoma Multiforme Clinical Trials in New York, New York

7 studies are recruiting for glioblastoma multiforme in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

   The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Lenox Hill Hospital, New York, New York

   Locations

   9 in total

   Run by

   Boston Scientific Corporation

   See if you can join NCT05303467 on ClinicalTrials.gov

2. Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

   The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   New York University Langone's Perlmutter Cancer Institute, New York, New York

   Locations

   2 in total

   Run by

   Baptist Health South Florida

   See if you can join NCT06991101 on ClinicalTrials.gov

3. Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

   The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Lenox Hill Brain Tumor Center, New York, New York

   Run by

   Northwell Health

   See if you can join NCT01269853 on ClinicalTrials.gov

4. Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

   Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with me…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Lenox Hill Brain Tumor Center, New York, New York

   Run by

   Northwell Health

   See if you can join NCT05271240 on ClinicalTrials.gov

5. Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

   This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Lenox Hill Brain Tumor Center, New York, New York

   Run by

   Northwell Health

   See if you can join NCT05954858 on ClinicalTrials.gov

6. Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

   This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Lenox Hill Brain Tumor Center, New York, New York

   Run by

   Northwell Health

   See if you can join NCT05979064 on ClinicalTrials.gov

7. Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

   The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center - Herbert Irving Pavilion, New York, New York

   Locations

   8 in total

   Run by

   Orbus Therapeutics, Inc.

   See if you can join NCT05879367 on ClinicalTrials.gov